Latest Insider Transactions at Greenwich Life Sciences, Inc. (GLSI)
This section provides a real-time view of insider transactions for Greenwich Life Sciences, Inc. (GLSI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Greenwich LifeSciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Greenwich LifeSciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 02
2022
|
Jaye Thompson VP Clinical Reg Affairs |
BUY
Open market or private purchase
|
Direct |
250
+0.1%
|
$3,250
$13.98 P/Share
|
|
Dec 02
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
1,000
+0.04%
|
$13,000
$13.84 P/Share
|
|
Nov 02
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
2,000
+0.07%
|
$16,000
$8.79 P/Share
|
|
Oct 14
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
3,000
+0.11%
|
$27,000
$9.75 P/Share
|
|
Oct 07
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
2,000
+0.07%
|
$18,000
$9.72 P/Share
|
|
Sep 30
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
1,000
+0.04%
|
$9,000
$9.46 P/Share
|
|
Sep 29
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
1,000
+0.04%
|
$9,000
$9.23 P/Share
|
|
Jun 24
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Indirect |
6,465
+0.24%
|
$58,185
$9.13 P/Share
|
|
Jun 24
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
22,535
+0.83%
|
$202,815
$9.13 P/Share
|
|
Jun 16
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
8,000
+0.3%
|
$56,000
$7.13 P/Share
|
|
Jun 14
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
12,000
+0.45%
|
$84,000
$7.91 P/Share
|
|
Jun 10
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
12,000
+0.45%
|
$96,000
$8.33 P/Share
|
|
Jun 09
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
4,500
+0.36%
|
$45,000
$10.9 P/Share
|
|
Jun 07
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
6,000
+0.48%
|
$48,000
$8.55 P/Share
|
|
Jun 03
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
9,250
+0.74%
|
$74,000
$8.35 P/Share
|
|
Jun 02
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
6,774
+0.55%
|
$47,418
$7.38 P/Share
|
|
Apr 25
2022
|
Frank Joseph Daugherty Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+1.1%
|
$16,000
$16.25 P/Share
|
|
Apr 21
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
6,000
+0.49%
|
$96,000
$16.09 P/Share
|
|
Apr 19
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
6,000
+0.49%
|
$96,000
$16.74 P/Share
|
|
Apr 19
2022
|
Jaye Thompson VP Clinical Reg Affairs |
BUY
Open market or private purchase
|
Direct |
500
+0.19%
|
$8,000
$16.74 P/Share
|
|
Feb 11
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
5,500
+0.45%
|
$104,500
$19.8 P/Share
|
|
Feb 04
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
5,000
+0.42%
|
$95,000
$19.59 P/Share
|
|
Jan 31
2022
|
Jaye Thompson VP Clinical Reg Affairs |
BUY
Open market or private purchase
|
Direct |
500
+0.2%
|
$9,000
$18.47 P/Share
|
|
Jan 21
2022
|
Kenneth Hallock Director |
BUY
Open market or private purchase
|
Direct |
300
+0.08%
|
$4,800
$16.32 P/Share
|
|
Jan 21
2022
|
Jaye Thompson VP Clinical Reg Affairs |
BUY
Open market or private purchase
|
Direct |
500
+0.2%
|
$8,000
$16.33 P/Share
|
|
Jan 18
2022
|
Jaye Thompson VP Clinical Reg Affairs |
BUY
Open market or private purchase
|
Direct |
500
+0.2%
|
$9,000
$18.87 P/Share
|
|
Jan 13
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
1,000
+0.08%
|
$19,000
$19.99 P/Share
|
|
Jan 13
2022
|
Frank Joseph Daugherty Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+1.11%
|
$19,000
$19.99 P/Share
|
|
Jan 13
2022
|
Jaye Thompson VP Clinical Reg Affairs |
BUY
Open market or private purchase
|
Direct |
1,000
+0.39%
|
$19,000
$19.99 P/Share
|
|
Jan 03
2022
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
2,050
+0.17%
|
$47,150
$23.82 P/Share
|
|
Dec 14
2021
|
David Mc Williams Director |
BUY
Open market or private purchase
|
Direct |
200
+0.03%
|
$5,400
$27.56 P/Share
|
|
Dec 14
2021
|
Frank Joseph Daugherty Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,111
+1.25%
|
$28,886
$26.99 P/Share
|
|
Dec 14
2021
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
1,840
+0.15%
|
$49,680
$27.17 P/Share
|
|
Apr 13
2021
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
2,700
+0.23%
|
$97,200
$36.98 P/Share
|
|
Nov 24
2020
|
Kenneth Hallock Director |
BUY
Open market or private purchase
|
Indirect |
1,000
+0.25%
|
$5,000
$5.39 P/Share
|
|
Nov 23
2020
|
Frank Joseph Daugherty Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+1.14%
|
$5,000
$5.1 P/Share
|
|
Nov 20
2020
|
Eric Rothe Director |
BUY
Open market or private purchase
|
Direct |
2,000
+0.63%
|
$10,000
$5.4 P/Share
|
|
Nov 20
2020
|
Kenneth Hallock Director |
BUY
Open market or private purchase
|
Indirect |
1,000
+0.25%
|
$5,000
$5.37 P/Share
|
|
Nov 20
2020
|
David Mc Williams Director |
BUY
Open market or private purchase
|
Direct |
1,500
+0.24%
|
$7,500
$5.4 P/Share
|
|
Nov 19
2020
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
2,000
+0.17%
|
$10,000
$5.4 P/Share
|
|
Nov 10
2020
|
Pankaj Amrit Patel > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
561,798
-100.0%
|
-
|
|
Sep 29
2020
|
Kinnary Patel > 10% Shareholder |
BUY
Exercise of conversion of derivative security
|
Indirect |
129,400
+39.45%
|
-
|
|
Sep 29
2020
|
Kenneth Hallock Director |
BUY
Open market or private purchase
|
Indirect |
8,333
+2.07%
|
$33,332
$4.6 P/Share
|
|
Sep 29
2020
|
Snehal Patel CEO and CFO |
BUY
Open market or private purchase
|
Direct |
16,667
+1.39%
|
$66,668
$4.6 P/Share
|
|
Sep 29
2020
|
David Mc Williams Director |
BUY
Exercise of conversion of derivative security
|
Direct |
171,622
+5.84%
|
-
|
|
Sep 29
2020
|
Kenneth Hallock Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
116,575
+9.77%
|
-
|
|
Sep 29
2020
|
Snehal Patel CEO and CFO |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,360,635
+21.9%
|
-
|
|
Sep 29
2020
|
Snehal Patel CEO and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
304,489
+6.23%
|
-
|